Baxter International Inc. (BAX: Quote) said results from two large, international multicenter trials demonstrated that a low glucose peritoneal dialysis, or PD, regimen favorably impacted metabolic measures important for end-stage renal disease patients with diabetes, including blood glucose control and selected lipids.
Results from the combined IMPENDIA/EDEN trials showed that a low-glucose PD regimen led to clinically and statistically significant reductions in serum levels of HbA1c in adult PD patients with diabetes. HbA1c is the standard marker for assessing blood glucose control in adult PD patients with diabetes
In the studies, significant reductions also were seen with certain lipid parameters including serum triglycerides, VLDL-cholesterol and apolipoprotein B following a low-glucose PD regimen.
"A low-glucose prescription should be considered when managing diabetic patients on peritoneal dialysis," said Joanne Bargman, MD, University Health Network and professor of Medicine at the University of Toronto and presenting study investigator. "The data demonstrate low glucose PD regimens may be beneficial in aiding the management of glucose and lipid levels in diabetic PD patients."
Click here to receive FREE breaking news email alerts for Baxter International Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.com
Business News